Scientist/Senior Scientist

What you'll do In your role as a Scientist, you will: - Develop functional assays and pre-clinical models to measure endothelial cell function - Collaborate with our Functional Genomics and Predictive Modeling teams to test reprogramming hypotheses at scale - Measure the impact of mRNA reprogramming medicines on endothelial cell function - Engineer in vivo nucleic acid delivery methods for endothelial cells - Analyze and interpret experimental data to drive pre-clinical decision making

Requirements - Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years) - Experience with primary cell isolation and functional characterization - Experience working with mouse models (e.g. kidney, cardiovascular, or cognitive disease models) - Experience with transgenic manipulation of primary cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery) Nice to have - History of contributing to a drug development program at the pre-clinical or clinical development stage - Experience leading the design and execution of pre-clinical studies in mouse models - Experience with single cell genomics methods - Experience with pooled screening approaches using bulk or single cell read-outs (e.g.

CRISPR fitness screens, Perturb/CROP-seq)

Benefits NewLimit offers generous benefits to ensure our team can focus on our mission: - Health, dental, and vision insurance - 401(k) with company match - Paid parental leave - Industry-leading paid time off (PTO) - 20 days/year for all employees + holidays - Meals and snacks on-site Salary Range: $130,000 to $180,000.

Compensation for the role will depend on a number of factors, including a candidate's qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.